Imagine a world where a simple treatment could shield the most vulnerable among us—infants—from a potentially life-threatening virus. That world is becoming a reality, thanks to groundbreaking advancements in medical science. But here's where it gets controversial: can we truly rely on monoclonal antibodies to protect our youngest against respiratory syncytial virus (RSV), and what does this mean for the future of pediatric healthcare?
RSV, a common respiratory virus, often presents as a mild, cold-like illness during the typical respiratory virus season. However, for infants under six months and older adults over 65, it can escalate into severe health complications, including bronchiolitis, pneumonia, and even sepsis. These conditions frequently require extended hospital stays, placing a significant burden on both families and healthcare systems. And this is the part most people miss: while RSV might seem like just another cold, its impact on vulnerable populations can be devastating.
Since 2022, the European Union has authorized immunization products to combat RSV in infants and older adults. These include long-acting monoclonal antibodies administered to newborns during the winter season and vaccines for pregnant individuals to safeguard their babies during their first winter after birth. With the European RSV season returning to its pre-pandemic pattern—spanning from October to April—these interventions have become even more critical.
In a rapid communication published in Eurosurveillance, Savulescu et al. analyzed data from three European countries with RSV immunization programs during the 2024–25 winter season. Their focus? The effectiveness of the long-acting monoclonal antibody nirsevimab in preventing RSV infections. But here’s the kicker: while the results are promising, they also raise questions about the longevity of protection and the need for ongoing monitoring.
The researchers conducted a case-control study involving 4,102 hospitalized children under two years old in Belgium, Portugal, and Spain. Of these, 791 RSV-positive cases and 1,410 RSV-negative controls were included in the analysis. Children were considered immunized if they received nirsevimab between September 2024 and May 2025, regardless of dose, age, or weight at the time of administration.
The findings were striking: immunization with nirsevimab demonstrated a pooled overall effectiveness of 79% in preventing RSV-related hospitalizations during the 2024–25 European winter season. Among infants aged 0–6 months—the group at highest risk for severe RSV illness—the effectiveness was 80%. But here's where it gets tricky: the protection wasn’t permanent. Effectiveness declined over time, dropping from 85% in the first month to 69% after three months.
This raises a critical question: How can we ensure sustained protection for infants, especially during their most vulnerable months? The authors emphasize the need for ongoing monitoring of immunization effectiveness in future seasons. Is this a temporary solution, or can we refine these treatments to provide longer-lasting immunity? We’d love to hear your thoughts in the comments.
For more details, refer to the study published in Eurosurveillance (2025). DOI: 10.2807/1560-7917.ES.2025.30.45.2500816.
Provided by the European Centre for Disease Prevention and Control (ECDC).
Citation: Monoclonal antibodies effectively prevent respiratory syncytial virus in infants (2025, November 13). Retrieved 13 November 2025 from https://medicalxpress.com/news/2025-11-monoclonal-antibodies-effectively-respiratory-syncytial.html.
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for information purposes only.
